Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

  • 2026 - Best Places to Work - Badge (1).png
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
200 Technology Square
Cambridge, MA
Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

  • Featured Employer

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. Our workforce has grown significantly over the last few years as we have rapidly scaled to become a global commercial company. With more than 5,500 people around the world, we are focused on creating an environment that is rooted in a strong sense of belonging. Hear from our changemakers.

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.
We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.
NEWS
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
The Nasdaq indicated that there was a record amount of biotech initial public offerings this year, including some individual record-breakers—Moderna, Allogene Therapeutics and Rubius Therapeutics. The total for the year is around $8.2 billion raised, breaking 2014’s record of $6.5 billion.
The long-awaited and massively hyped initial public offering of Moderna Therapeutics hit the market yesterday. The company sold approximately 26.3 million shares priced at $23 a share. This exceeded the revised goal of $600 million by about $4.3 million.
Moderna Therapeutics raised some eyebrows last week when it refiled with the Securities and Exchange Commission (SEC), raising its goal for its initial public offering from $500 million to $600 million. The company, which has no products on the market, is fantastic at raising money, but some analysts wonder if the company is overvalued.
The Cambridge, Mass.-based biotech company, which had proposed a $500 million initial public offering (IPO) earlier this month, came back Wednesday with a new goal of $600 million.
Vivek Ramaswamy’s Roivant Sciences, the umbrella company to 14 Vant companies, including Datavant, Enzyvant Sciences, Urovant Sciences and others, raised another $200 million in equity financing.
As a private company, Moderna has amassed a significant fortune of billions of dollars and a valuation of about $7 billion – all of this without any marketed product in the company’s field of messenger RNA (mRNA).
A summary of IPOs from companies in the biotech and pharma world since November 1, 2018.
In a survey of more than 8,000 people in the biotech and pharma industry for Science, Regeneron Pharmaceuticals, topped the list.
JOBS
  • 20251103 - FINAL PROOF - 2026 HOTBED MAPS - GENETOWN - Moderna.png
IN THE PRESS